Today, central nervous system (CNS) disorders are being redefined through molecular signatures, circuit-level dysfunction, and continuously captured digital phenotypes. This shift is not incremental it fundamentally alters how therapies must be discovered, developed, and approved. Organizations that continue to anchor development programs in broad diagnostic labels and legacy endpoints face a growing risk of failure. Not because their science lacks merit, but because their development strategies are misaligned with biological reality.